Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter to the editor: Improvement in the prediction of cervical lymph node metastasis in esophageal squamous cell carcinoma based on ultrasonography and machine learning.

International journal of surgery (London, England)·2025
Same author

Clinical value of serum HBV RNA in patients with chronic hepatitis B during antiviral therapy.

PeerJ·2025
Same author

Ultrasound characterization of superficial lymph nodes in HIV patients with lymphadenopathy.

Frontiers in medicine·2025
Same author

Diagnostic nomogram based on ultrasound and clinical data of predicting malignant lymph nodes in HIV patients with lymphadenopathy.

Frontiers in cellular and infection microbiology·2025
Same author

Case Report: Multidisciplinary management of primary omental pregnancy involving intraoperative ultrasound.

Frontiers in medicine·2025
Same author

Coexisting tubal pregnancy and intrauterine pregnancy during a natural pregnancy, first diagnosed via ultrasonography: A case report.

Medicine·2025

Related Experiment Video

Updated: Jun 30, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Early on-treatment dynamics predicting hepatitis B e antigen seroconversion in chronic hepatitis B.

Kai Yu1, Huaguo Shao2, Qiaofei Jin1

  • 1Department of Hepatology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University (Hangzhou Sixth People's Hospital), Hangzhou, Zhejiang, China.

Frontiers in Immunology
|June 29, 2026
PubMed
Summary

Early changes in Hepatitis B e antigen (HBeAg), hepatitis B surface antigen (HBsAg), GGT, and albumin predict long-term HBeAg seroconversion in patients on nucleos(t)ide analogues therapy.

Keywords:
HBeAg seroconversionLASSO logistic regression modelchronic hepatitis Bnucleos(t)ide analogues therapyprediction model

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Experiment Videos

Last Updated: Jun 30, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis B e antigen (HBeAg) loss and anti-HBe appearance signify a key milestone in nucleos(t)ide analogues (NAs) therapy.
  • Static baseline biomarkers poorly predict this durable immunological event.
  • Early dynamic parameters during the initial 12 weeks of NA therapy may offer superior prognostic information.

Purpose of the Study:

  • To develop a predictive model for week-60 HBeAg seroconversion (SR).
  • To integrate week-12 changes in serum biochemical and virological markers for enhanced prediction.
  • To evaluate the model's performance against baseline values.

Main Methods:

  • Collected serum biochemical and virological data from HBeAg-positive patients on NA treatment.
  • Derived difference, ratio, and absolute week-12 values for key parameters.
  • Utilized least absolute shrinkage and selection operator (LASSO) logistic regression with ten-fold cross-validation to build a multi-variable model.

Main Results:

  • 38.24% of patients achieved HBeAg SR.
  • An eight-variable signature involving dynamic changes in HBeAg, HBsAg, GGT, and albumin was selected.
  • The multi-variable model achieved high AUC (0.975 in training, 0.721 in testing) with excellent sensitivity and specificity.

Conclusions:

  • Integrated early on-treatment dynamics of HBeAg, HBsAg, GGT, and albumin predict subsequent HBeAg SR.
  • The developed eight-variable model can aid in patient monitoring.
  • This model may inform alternative treatment strategies for patients undergoing NA therapy.